These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 30265523)

  • 21. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies.
    Khambhla E; Shah V; Baviskar K
    Curr Pharm Des; 2016; 22(19):2913-22. PubMed ID: 27033697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current advances in delivery of biotherapeutics across the blood-brain barrier.
    Rajadhyaksha M; Boyden T; Liras J; El-Kattan A; Brodfuehrer J
    Curr Drug Discov Technol; 2011 Jun; 8(2):87-101. PubMed ID: 21513485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody therapies in CNS diseases.
    Freskgård PO; Urich E
    Neuropharmacology; 2017 Jul; 120():38-55. PubMed ID: 26972827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central nervous system delivery of molecules across the blood-brain barrier.
    Gosselet F; Loiola RA; Roig A; Rosell A; Culot M
    Neurochem Int; 2021 Mar; 144():104952. PubMed ID: 33400964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regenerative therapies for central nervous system diseases: a biomaterials approach.
    Tam RY; Fuehrmann T; Mitrousis N; Shoichet MS
    Neuropsychopharmacology; 2014 Jan; 39(1):169-88. PubMed ID: 24002187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendrimer advances for the central nervous system delivery of therapeutics.
    Xu L; Zhang H; Wu Y
    ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.
    Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S
    Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
    Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
    Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system.
    Zlokovic BV; Apuzzo ML
    Neurosurgery; 1997 Apr; 40(4):805-12; discussion 812-3. PubMed ID: 9092854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic modalities to address nondrugable protein interaction targets.
    De Souza EB; Cload ST; Pendergrast PS; Sah DW
    Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system.
    Zlokovic BV; Apuzzo ML
    Neurosurgery; 1997 Apr; 40(4):789-803; discussion 803-4. PubMed ID: 9092853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnologies: a strategy to overcome blood-brain barrier.
    De Rosa G; Salzano G; Caraglia M; Abbruzzese A
    Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-based therapies for Huntington's disease: current status and future directions.
    Denis HL; David LS; Cicchetti F
    Neurobiol Dis; 2019 Dec; 132():104569. PubMed ID: 31398458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.